MedPage Today· @medpagetoday · X·· 2026-04-21Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Investigational zoldonrasib was well tolerated and showed encouraging clinical activity in previously treated KRAS G12D-mutated non-small cell lung cancer, according to a phase I study. #AACR26
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: MedPage Today · x.com